



[Go to Product page](#)

Datasheet for ABIN1045821  
**anti-Kanamycin antibody**

1 Image

6 Publications

### Overview

Quantity: 100 µg

Target: Kanamycin

Reactivity: Chemical

Host: Mouse

Clonality: Monoclonal

Application: ELISA

### Product Details

Immunogen: Kanamycin-BSA conjugate

Clone: 3F7C11

Isotype: IgG1, IgG1 kappa

Cross-Reactivity (Details): No significant cross-reactivity or interference was observed

Purification: Protein G purified

Purity: > 95 %

### Target Details

Target: Kanamycin

Abstract: [Kanamycin Products](#)

Target Type: Chemical

Background: Amkin, biograncetin, enterokan

## Application Details

---

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

## Handling

---

Format: Liquid

Buffer: Preservative: 0.03 % Proclin 300  
Constituents: 50 % Glycerol, 0.01M PBS, PH 7.4

Preservative: ProClin

Precaution of Use: This product contains ProClin: a POISONOUS AND HAZARDOUS SUBSTANCE, which should be handled by trained staff only.

Handling Advice: Avoid freeze and thaw cycles.

Storage: -20 °C,-80 °C

Storage Comment: Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.


## Publications

---

Product cited in: Harrop, McDonnell, Brigham-Burke, Lyn, Minton, Tan, Dede, Spampanato, Silverman, Hensley, DiPrinzio, Emery, Deen, Eichman, Chabot-Fletcher, Truneh, Young: "Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth." in: **The Journal of biological chemistry**, Vol. 273, Issue 42, pp. 27548-56, (1998) ([PubMed](#)).

Mauri, Ebner, Montgomery, Kochel, Cheung, Yu, Ruben, Murphy, Eisenberg, Cohen, Spear, Ware: "LIGHT, a new member of the TNF superfamily, and lymphotoxin alpha are ligands for herpesvirus entry mediator." in: **Immunity**, Vol. 8, Issue 1, pp. 21-30, (1998) ([PubMed](#)).

There are more publications referencing this product on: [Product page](#)



## ELISA

**Image 1.** Affinity determination of anti-kanamycin specific mAb against kanamycin-BSA conjugate. A microtiter plate was coated with respective antibiotic-BSA conjugate and remaining binding sites were blocked. Subsequently, antibody dilutions in the range from 9.76 ng·mL<sup>-1</sup> to 1250 ng·mL<sup>-1</sup> were applied and afterward labelled with mouse IgG-specific HRPO-conjugated secondary antibody. Absorbance was measured after 10 min of ABTS substrate incubation. Source: PMID33265942